Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.63 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | PRNP | P04156 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 5/20 | 0.49 |
| ▸ | CA2 | P00918 | 5/20 | 0.49 |
| ▸ | CA12 | O43570 | 4/20 | 0.49 |
| ▸ | CA9 | Q16790 | 4/20 | 0.49 |
| ▸ | PFKFB3 | Q16875 | 2/20 | 0.48 |
| ▸ | PFKFB4 | Q16877 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4198555 | 0.84 | KDM4E (0.63) | KDM4EMAPTALDH1A1MAPK1NPSR1 | |
| SCHEMBL761926 | 0.84 | KDM4E (0.63) | KDM4EMAPTALDH1A1MAPK1NPSR1 | |
| SCHEMBL14468670 | 0.83 | KDM4E (0.70) | KDM4EMAPTALDH1A1MAPK1NPSR1 | |
| SCHEMBL14447520 | 0.81 | KDM4E (0.60) | KDM4EMAPTALDH1A1MAPK1NPSR1 | |
| SCHEMBL12230254 | 0.77 | PFKFB3 (0.67) | KDM4EMAPTALDH1A1POLBPKM | |
| SCHEMBL14014139 | 0.76 | POLB (0.76) | KDM4EMAPTALDH1A1MAPK1NPSR1 | |
| SCHEMBL423483 | 0.75 | MAPT (0.68) | KDM4EMAPTALDH1A1MAPK1NPSR1 | |
| SCHEMBL4802533 | 0.74 | CA2 (0.53) | RAB9ANPC1CA1CA2CA12 | |
| SCHEMBL18358985 | 0.72 | ALDH1A1 (0.62) | KDM4EMAPTALDH1A1MAPK1NPSR1 | |
| SCHEMBL12230000 | 0.72 | PRNP (0.66) | KDM4EMAPTALDH1A1MAPK1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013173506-A2 | METHOD OF TREATING MUSCULAR DEGRADATION | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | WO | disclosed |
| US-20130310340-A1 | METHOD OF TREATING MUSCULAR DEGRADATION | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-20090227555-A2 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-20090227555-A2 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-20090227555-A2 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-20090042852-A1 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | US | disclosed |
| US-20090042852-A1 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | US | disclosed |
| US-20090042852-A1 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | US | disclosed |
| EP-1836189-A1 | NOVEL PYRIDINE COMPOUNDS | AstraZeneca AB (SE) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006073361-A9 | NOVEL PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | disclosed |
| WO-2006073361-A1 | NOVEL PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042852-A1 | Novel Pyridine Compounds | P2RY12, P2RY11, P2RY1 | KDM4E 3376/4885MAPT 3696/4885ALDH1A1 1820/4885 |
| US-20130310340-A1 | METHOD OF TREATING MUSCULAR DEGRADATION | PYGM, CKMT1A; CKMT1B, SMN1; SMN2 | KDM4E 906/4885MAPT 2214/4885ALDH1A1 1984/4885 |
| US-20090227555-A2 | Novel Pyridine Compounds | P2RY12, P2RY1, P2RY11 | KDM4E 2316/4885MAPT 4295/4885ALDH1A1 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.